1-Year Results Reported for Tirzepatide, Ixekizumab Combo in Psoriatic Disease
The combination also improved systemic inflammation and metabolic measures, while 30.6% of psoriasis patients and 39.2% of arthritis patients met the primary endpoint.
4 Articles
4 Articles
Eli Lilly released results from two Phase 3b clinical trials that show that your Zepbound medicine can reduce the symptoms of psoriasis and psoriatic arthritis in overweight people. Exclusive material for subscribers. To have full access, access the material link and register.
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials Systemic inflammation and metabolic outcomes continued to improve or were sustained at one year with Taltz and Zepbound compared to Taltz …
1-Year Results Reported for Tirzepatide, Ixekizumab Combo in Psoriatic Disease
Results from phase 3b trials show a greater benefit at 52 weeks for patients with psoriasis or psoriatic arthritis treated with ixekizumab plus tirzepatide vs ixekizumab alone. Medscape Medical News
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
